Selenium regulation of thioredoxin reductase activity and mRNA levels in rat liver

Hadley, Kevin; Sunde, Roger A.

doi:10.1016/s0955-2863(01)00189-9

Cited by 83 publications

(80 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differential incorporation of selenium into selenoproteins, first described by Behne et al (9), was also noted by other investigators as new selenoproteins were discovered (10)(11)(12)(13). These additional selenoproteins expanded the array of both biochemical and transcript-based biomarkers of selenium status in our studies (14)(15)(16)(17)(18). The identification of the complete selenoproteome (19) further expanded the number of selenoprotein transcripts as "molecular biomarkers" for the assessment of selenium status and requirements in rodents (20)(21)(22)(23) and is helping researchers to better understand the hierarchy of selenium incorporation into selenoproteins.…”

Section: Introductionmentioning

confidence: 82%

Insights for Setting of Nutrient Requirements, Gleaned by Comparison of Selenium Status Biomarkers in Turkeys and Chickens versus Rats, Mice, and Lambs

Sunde

Taylor

2016

Advances in Nutrition

View full text Add to dashboard Cite

To gain insights into nutrient biomarkers and setting of dietary nutrient requirements, selenium biomarker levels and requirements in response to multiple graded levels of dietary selenium were compared between day-old turkeys and chickens versus weanling rats and mice and 2-d-old lambs supplemented with sodium selenite. In rodents, there was no significant effect of dietary selenium on growth, indicating that the minimum selenium requirement was <0.007 mg Se/g diet. In contrast, there was a significant effect in turkeys, chicks, and lambs, which showed selenium requirements for growth of 0.05, 0.025, and 0.05 mg Se/g diet, respectively. Liver glutathione peroxidase (GPX) 1 activity fell in all species to <4% of selenium-adequate levels, plasma GPX3 activity fell to <3% in all species except for mice, and liver GPX4 activity fell to <10% in avians but only to ;50% of selenium-adequate levels in rodents. Selenium-response curves for these biomarkers reached well-defined plateaus with increasing selenium supplementation in all species, collectively indicating minimum selenium requirements of 0.06-0.10 mg Se/g for rats, mice, and lambs but 0.10-0.13 mg Se/g for chicks and 0.23-0.33 mg Se/g for turkeys. In contrast, increasing dietary selenium did not result in well-defined plateaus for erythrocyte GPX1 activity and liver selenium in most species. Selenium-response curves for GPX1 mRNA for rodents and avians had well-defined plateaus and similar breakpoints. GPX4 mRNA was not significantly regulated by dietary selenium in rodents, but GPX4 mRNA in avians decreased in selenium deficiency to ;35% of selenium-adequate plateau levels. Notably, no selenoprotein activities or mRNA were effective biomarkers for supernutritional selenium status. Robust biomarkers, such as liver GPX1 and plasma GPX3 activity for selenium, should be specific for the nutrient, fall dramatically in deficiency, and reach well-defined plateaus. Differences in biomarker-response curves may help researchers better understand nutrient metabolism and targeting of tissues in deficiency, thus to better characterize requirements. Adv Nutr 2016;7:1129-38.

show abstract

Section: Introductionmentioning

confidence: 82%

Insights for Setting of Nutrient Requirements, Gleaned by Comparison of Selenium Status Biomarkers in Turkeys and Chickens versus Rats, Mice, and Lambs

Sunde

Taylor

2016

Advances in Nutrition

View full text Add to dashboard Cite

show abstract

“…At this point, it has to be mentioned that selenium (Se) is essential for the activity of TR1, and adding Se at 10 M to the medium of cultured cells increases cellular TR1 activity by as much as 60-fold Gallegos et al, 1997). In vitro and in vivo studies described a missing relation between TR activity and TR1 mRNA expression (Hadley and Sunde, 2001;Hara et al, 2001;Wu et al, 2003), which might be influenced by the origin of the cell (Miller et al, 2002). Consequently, we cannot exclude an relevant impact by Se on our mRNA expression data, because all of our cell culture experiments were performed in medium that was not Se supplemented.…”

Section: Lechner Et Almentioning

confidence: 97%

Thioredoxin Reductase 1 Expression in Colon Cancer: Discrepancy between In Vitro and In Vivo Findings

Lechner

Müller‐Ladner

Neumann

et al. 2003

Laboratory Investigation

View full text Add to dashboard Cite

SUMMARY:Thioredoxin and thioredoxin reductase 1 (TR1) are redox proteins that have been implicated in cellular events such as proliferation, transformation, and apoptosis. Analysis of the expression and localization of TR1 in different normal and cancer cell lines and in colon tissues (normal, neoplastic, or inflamed) was performed using reverse transcription-PCR and in situ hybridization. TR1 mRNA was expressed in all analyzed tissues with TR mRNA-positive cells restricted to the stroma of colon crypts, partly being CD3 or CD56 positive. In neoplastic areas of colonic cancer tissue, a loss of TR was obvious. None of the epithelial cells in colonic mucosa expressed TR mRNA, whereas more than 70% of HT-29 cells grown in monolayer were positive for TR. In contrast, HT-29 cells, grown as spheroids or as tumors in SCID mice, were negative for TR. In contrast to these in vitro findings and previous studies, there is no evidence that TR plays a significant role in vivo in normal cell growth in colonic epithelial cells. The mechanism underlying the loss of TR1-positive/CD3-positive/CD56-positive cells or the biologic consequence of this phenomenon observed in neoplastic colonic tissue remains to be clarified. (Lab Invest 2003, 83:1321-1331.

show abstract

“…21,22 Selenium has also been shown to disrupt the androgenic signaling pathway, 12 which has been shown to regulate the expression level of SELENBP1. Hence, selenium effects on the SELENBP1 expression in HOSE cells and ovarian cancer cells were investigated.…”

Section: Effect Of Selenium On Selenbp1 Expressionmentioning

confidence: 99%

Selenium binding protein 1 in ovarian cancer

Huang

Park

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Selenium binding protein 1 (SELENBP1) was identified to be the most significantly down-regulated protein in ovarian cancer cells by a membrane proteome profiling analysis. SELENBP1 expression levels in 4 normal ovaries, 8 benign ovarian tumors, 12 borderline ovarian tumors and 141 invasive ovarian cancers were analyzed with immunohistochemical assay. SELENBP1 expression was reduced in 87% cases of invasive ovarian cancer (122/141) and was significantly reduced in borderline tumors and invasive cancers (p < 0.001). Cox multivariate analysis within the 141 invasive cancer tissues showed that SELENBP1 expression score was a potential prognostic indicator for unfavorable prognosis of ovarian cancer (hazard ratio [HR], 2.18; 95% CI 5 1.22-3.90; p 5 0.009). Selenium can disrupt the androgen pathway, which has been implicated in modulating SELENBP1 expression. We investigated the effects of selenium and androgen on normal human ovarian surface epithelial (HOSE) cells and cancer cells. Interestingly, SELENBP1 mRNA and protein levels were reduced by androgen and elevated by selenium treatment in the normal HOSE cells, whereas reversed responses were observed in the ovarian cancer cell lines. These results suggest that changes of SELENBP1 expression in malignant ovarian cancer are an indicator of aberration of selenium/androgen pathways and may reveal prognostic information of ovarian cancer. ' 2005 Wiley-Liss, Inc.Key words: ovarian cancer; membrane proteome profiling; 2-D PAGE; selenium binding protein 1; prognostic marker; androgen; methylselenocysteine Despite advances in cancer therapeutic agents in recent years, approximately 14,000 women still die of ovarian cancer each year in the United States, making it the most lethal of the gynecological malignancies. 1 Currently, surgical debulking followed by chemotherapy is the major treatment approach for ovarian cancer. Most cases of ovarian cancer are diagnosed at advanced stages when the prognosis for 5-year survival is poor. 2 Developing new diagnostic technique and improving current therapeutic strategy are the main directions to fight this morbid disease.Multiple genomic and proteomic approaches have been applied to identify disease-associated biomarkers for diagnosis and disease management. Applying cDNA and oligo microarray technology have enabled scientists to look into the global differences in gene expression between normal and cancer cells. 3 For proteomic approaches, two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) followed by protein identification using mass spectrometry has been the primary technique for biomarker discovery. 4,5 Membrane-associated proteins have been suggested to be a potential resource for biomarker screening. 6 In our pilot study of the use of 2-D PAGE to profile membrane-associated proteins of normal ovarian surface epithelial cells and ovarian cancer cell lines, selenium binding protein 1 (SELENBP1) was identified as the most significantly down-regulated protein in the cancer cells.The human selenium binding protein gene (...

show abstract

Selenium regulation of thioredoxin reductase activity and mRNA levels in rat liver

Cited by 83 publications

References 10 publications

Insights for Setting of Nutrient Requirements, Gleaned by Comparison of Selenium Status Biomarkers in Turkeys and Chickens versus Rats, Mice, and Lambs

Insights for Setting of Nutrient Requirements, Gleaned by Comparison of Selenium Status Biomarkers in Turkeys and Chickens versus Rats, Mice, and Lambs

Thioredoxin Reductase 1 Expression in Colon Cancer: Discrepancy between In Vitro and In Vivo Findings

Selenium binding protein 1 in ovarian cancer

Contact Info

Product

Resources

About